Moxotens (Moxonidine)

Moxonidine selectively activates imidazoline I1 receptors in the brainstem. This activation suppresses sympathetic outflow, leading to decreased peripheral vascular resistance and a reduction in both systolic and diastolic blood pressure.

The dosage of Moxotens is individualized by a qualified prescriber based on the patient’s clinical condition, response, and any co‑existing medical issues. Patients should follow the specific dosing instructions provided by their healthcare professional.

Safety data for moxonidine in pregnancy are limited, and the product should only be used if the potential benefit outweighs the risk. Breastfeeding is not recommended unless the prescriber determines that the advantages to the mother exceed possible risks to the infant.

To request Moxotens, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxotens (moxonidine) differs from many beta‑blockers or ACE inhibitors by targeting central imidazoline I1 receptors rather than peripheral receptors or enzymes. This mechanism can provide effective blood‑pressure control with a distinct side‑effect profile, making it a useful alternative for patients who do not tolerate other classes.

Moxotens should be stored at ambient temperature, ideally below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Moxotens is taken orally, usually with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water and do not crush or chew it unless specifically instructed.

Serious risks include severe hypotension, bradycardia, hepatic dysfunction, and rare allergic reactions. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, yellowing of the skin or eyes, or signs of an allergic response such as swelling or rash.

Moxotens is contraindicated in patients with known hypersensitivity to moxonidine or any excipients in the tablet. It should also be avoided in individuals with severe hepatic impairment, uncontrolled heart failure, or those taking certain central antihypertensives that could cause excessive blood‑pressure lowering.